Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Seymour

Showing results (1-10 of 439) with videos related to

Pageof 44
Sort By:
Blood|February 15, 2024
Risk/benefit of BTK/venetoclax combos: the context matters!John F Seymour
The New England Journal of Medicine|August 20, 2025
GM-CSF in Autoimmune Pulmonary Alveolar ProteinosisJohn F Seymour
Seminars in Oncology|February 1, 2017
New Treatment Approaches To Indolent Non-Hodgkin's LymphomaJohn F Seymour
Seminars in Oncology|March 26, 2004
New treatment approaches to indolent non-Hodgkin's lymphomaJohn F Seymour
Blood Advances|December 29, 2021
Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2iJohn F Seymour
Blood|January 13, 2022
CLL12: a positive answer to a poorly phrased questionJohn F Seymour
Leukemia & Lymphoma|September 29, 2021
The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLLJohn F Seymour
Nature Reviews. Clinical Oncology|October 29, 2009
Hematology: Follicular lymphoma: maintenance therapy is (often) indicatedJohn F Seymour
Hematological Oncology|June 19, 2013
X. Extra-nodal lymphoma in rare localisations: bone, breast and testesJohn F Seymour
Leukemia & Lymphoma|December 8, 2011
Osteolytic bone lesions in non-transformed chronic lymphocytic leukemia are not as rare as suggestedJohn F Seymour
Pageof 44

Showing results (1-10 of 439) with videos related to

Sort By:
Pageof 44
Blood|February 15, 2024
Risk/benefit of BTK/venetoclax combos: the context matters!John F Seymour
The New England Journal of Medicine|August 20, 2025
GM-CSF in Autoimmune Pulmonary Alveolar ProteinosisJohn F Seymour
Seminars in Oncology|February 1, 2017
New Treatment Approaches To Indolent Non-Hodgkin's LymphomaJohn F Seymour
Seminars in Oncology|March 26, 2004
New treatment approaches to indolent non-Hodgkin's lymphomaJohn F Seymour
Blood Advances|December 29, 2021
Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2iJohn F Seymour
Blood|January 13, 2022
CLL12: a positive answer to a poorly phrased questionJohn F Seymour
Leukemia & Lymphoma|September 29, 2021
The tools to choose: applying indirect treatment comparisons to the selection of frontline targeted therapy for CLLJohn F Seymour
Nature Reviews. Clinical Oncology|October 29, 2009
Hematology: Follicular lymphoma: maintenance therapy is (often) indicatedJohn F Seymour
Hematological Oncology|June 19, 2013
X. Extra-nodal lymphoma in rare localisations: bone, breast and testesJohn F Seymour
Leukemia & Lymphoma|December 8, 2011
Osteolytic bone lesions in non-transformed chronic lymphocytic leukemia are not as rare as suggestedJohn F Seymour
Pageof 44